Minimal Residual Disease (MRD) Testing
News and reporting on minimal residual disease testing.
Guardant Health, Pfizer Partner to Use Liquid Biopsy to Aid Cancer Therapy Development
Pfizer intends to use Guardant's blood-based tests in global clinical trials, with specific plans to evaluate the clinical utility of its Reveal assay as clinical trial surrogate endpoint.
Invivoscribe's LabPMM Nabs NY State Approval for MRD Assay
The company can now offer the FLT3 ITD MRD Assay in New York state to assess measurable residual disease to guide treatment for acute myeloid leukemia patients.
Precision Oncology Investments Continue Amid Stubborn Operational Difficulties, Survey Shows
Premium
Precision Medicine Online's 2024 survey shows biomarker test expansion but low clinical trial enrollment and long wait times for advanced therapies.
A discussion at the Precision Medicine Tri-Con demonstrated that stakeholders are narrowing in on the challenges to realizing the promise of solid tumor MRD.
Tethis, Sheba Medical Center Trying to Predict Rectal Cancer Relapse Earlier With CTCs, ctDNA
Sheba researchers will use Tethis' technology to prepare patients' blood samples for circulating tumor cells and circulating tumor DNA analysis.